A cancer study sponsored by drug company GlaxoSmithKline has provided researchers with a surprising result: a 100% remission rate for the 12 participants. All of the study’s participants had a very specific type of advanced rectal cancer – mismatch-repair deficient colorectal cancer – that, due to its genetic traits, made it a good candidate for […]